AU3735000A - Modulation of substance p by gaba analogs and methods relating thereto - Google Patents

Modulation of substance p by gaba analogs and methods relating thereto

Info

Publication number
AU3735000A
AU3735000A AU37350/00A AU3735000A AU3735000A AU 3735000 A AU3735000 A AU 3735000A AU 37350/00 A AU37350/00 A AU 37350/00A AU 3735000 A AU3735000 A AU 3735000A AU 3735000 A AU3735000 A AU 3735000A
Authority
AU
Australia
Prior art keywords
modulation
substance
methods relating
gaba analogs
gaba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37350/00A
Inventor
Philip John Magistro Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU3735000A publication Critical patent/AU3735000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU37350/00A 1999-05-05 2000-03-10 Modulation of substance p by gaba analogs and methods relating thereto Abandoned AU3735000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13261499P 1999-05-05 1999-05-05
US60132614 1999-05-05
PCT/US2000/006199 WO2000067742A2 (en) 1999-05-05 2000-03-10 Use of gaba analogues for the modulation of substance p

Publications (1)

Publication Number Publication Date
AU3735000A true AU3735000A (en) 2000-11-21

Family

ID=22454836

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37350/00A Abandoned AU3735000A (en) 1999-05-05 2000-03-10 Modulation of substance p by gaba analogs and methods relating thereto

Country Status (2)

Country Link
AU (1) AU3735000A (en)
WO (1) WO2000067742A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1202725E (en) * 1999-07-22 2007-07-11 Universuty Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
DE60210760T2 (en) * 2001-04-23 2006-11-23 F. Hoffmann-La Roche Ag USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENEFICIAL PROSTATE HYPERPLASIA
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
MXPA05006209A (en) * 2002-12-13 2005-08-19 Warner Lambert Co Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders.
MXPA05006656A (en) * 2002-12-20 2006-02-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING alpha2.
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
MX2009006080A (en) * 2006-12-08 2009-07-14 Xenoport Inc Use of prodrugs of gaba analogs for treating diseases.
US8686040B2 (en) * 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
WO2016195723A1 (en) * 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (en) * 1996-07-24 2005-10-31 Warner Lambert Co Isobutylgabe and its derivatives useful in relieving pains

Also Published As

Publication number Publication date
WO2000067742A3 (en) 2001-08-16
WO2000067742A2 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
AU6883798A (en) Method of anesthesia
AU3867400A (en) Methods of using bioelastomers
AU1345700A (en) Method of sterilizing females
AU4005499A (en) Method of controlling usage of software components
AU8289298A (en) Phosphocholines of retinoids
AU9469198A (en) New improved formulation for treatment of osteoporosis
AU5799098A (en) Preparation of gabapentin
AU2003281327A1 (en) Antisense modulation of tfg-beta 2 expression
AU3789399A (en) Indolicidin analogs and methods of using same
AU5934598A (en) Manufacture of ascorbyl monophosphates
AU7902400A (en) Method for the preparation of 5-carboxyphthalide
AU3735000A (en) Modulation of substance p by gaba analogs and methods relating thereto
PL338679A1 (en) Method of obtaining l-glutamic acid by fermentation
AU3938299A (en) Method of altering heartbeat
AU7876900A (en) Antisense modulation of fra-1 expression
AU4671000A (en) Method of enhancing insulin action
AU4994899A (en) Modulation of the phospholipase a2 pathway as a therapeutic
AU4981199A (en) Compositions and methods for modulating sexual activity
AU5737498A (en) Method for the preparation of alpha-bromo-lactam derivatives
AU7080798A (en) Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
AU1017199A (en) Analogs of vitamin e
AU1951701A (en) Methods for modulation of oocyte activation
AU1130901A (en) Method for the preparation of 5-carboxyphthalide
AU2668201A (en) Method for the production of optically active cyanohydrins using r-oxynitrilase
AU2382601A (en) Novel method of treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase